EP3383390A4 - PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS - Google Patents

PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS Download PDF

Info

Publication number
EP3383390A4
EP3383390A4 EP16871683.5A EP16871683A EP3383390A4 EP 3383390 A4 EP3383390 A4 EP 3383390A4 EP 16871683 A EP16871683 A EP 16871683A EP 3383390 A4 EP3383390 A4 EP 3383390A4
Authority
EP
European Patent Office
Prior art keywords
nociceptin receptor
piperidinyl compounds
piperidinyl
compounds
nociceptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16871683.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3383390A1 (en
Inventor
Nurulain T. Zaveri
Michael Meyer
V. Blair JOURNIGAN
Dennis Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astraea Therapeutics LLC
Original Assignee
Astraea Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58798102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3383390(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astraea Therapeutics LLC filed Critical Astraea Therapeutics LLC
Priority to EP24198979.7A priority Critical patent/EP4455145A3/en
Publication of EP3383390A1 publication Critical patent/EP3383390A1/en
Publication of EP3383390A4 publication Critical patent/EP3383390A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP16871683.5A 2015-12-02 2016-12-02 PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS Pending EP3383390A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24198979.7A EP4455145A3 (en) 2015-12-02 2016-12-02 Piperidinyl nociceptin receptor compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562261871P 2015-12-02 2015-12-02
PCT/US2016/064854 WO2017096323A1 (en) 2015-12-02 2016-12-02 Piperidinyl nociceptin receptor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24198979.7A Division EP4455145A3 (en) 2015-12-02 2016-12-02 Piperidinyl nociceptin receptor compounds

Publications (2)

Publication Number Publication Date
EP3383390A1 EP3383390A1 (en) 2018-10-10
EP3383390A4 true EP3383390A4 (en) 2019-11-20

Family

ID=58798102

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16871683.5A Pending EP3383390A4 (en) 2015-12-02 2016-12-02 PIPERIDINYL-nociceptin RECEPTOR COMPOUNDS
EP24198979.7A Pending EP4455145A3 (en) 2015-12-02 2016-12-02 Piperidinyl nociceptin receptor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24198979.7A Pending EP4455145A3 (en) 2015-12-02 2016-12-02 Piperidinyl nociceptin receptor compounds

Country Status (8)

Country Link
EP (2) EP3383390A4 (enrdf_load_html_response)
JP (4) JP7011596B2 (enrdf_load_html_response)
KR (2) KR102781748B1 (enrdf_load_html_response)
CN (1) CN108883103A (enrdf_load_html_response)
AU (3) AU2016365400C1 (enrdf_load_html_response)
CA (1) CA3006966A1 (enrdf_load_html_response)
IL (1) IL259726B (enrdf_load_html_response)
WO (1) WO2017096323A1 (enrdf_load_html_response)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883103A (zh) * 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN117642402A (zh) * 2021-07-14 2024-03-01 宜昌人福药业有限责任公司 一种螺哌啶环衍生物及其药物组合物、制备方法和用途
CA3224323A1 (en) 2021-07-14 2023-01-19 Jian Wang Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254895A1 (en) * 2000-01-20 2002-11-06 Eisai Co., Ltd. Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
EP1308439A1 (en) * 2000-08-10 2003-05-07 Welfide Corporation Proline derivatives and use thereof as drugs
WO2004056830A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2008060621A2 (en) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
WO2011029915A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
WO2011101409A1 (en) * 2010-02-19 2011-08-25 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2014157687A1 (ja) * 2013-03-29 2014-10-02 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４－トリアジン－６－カルボキサミド誘導体
WO2014174021A1 (en) * 2013-04-24 2014-10-30 Janssen Pharmaceutica Nv 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors for the treatment of cancer
WO2014184069A1 (en) * 2013-05-14 2014-11-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
WO2015044269A1 (en) * 2013-09-26 2015-04-02 Janssen Pharmaceutica Nv NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
EP2878601A1 (en) * 2012-07-27 2015-06-03 Riken Agent for treating or controlling recurrence of acute myelogenous leukemia
WO2016062789A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as nik inhibitors
WO2016062791A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2352702A1 (de) * 1973-10-20 1975-06-26 Hoechst Ag Basisch substituierte 1,4-dihydro-2hisochinolinderivate und verfahren zu ihrer herstellung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
DE69434294T2 (de) * 1993-12-23 2005-12-29 Eli Lilly And Co., Indianapolis Proteinkinase c-inhibitoren
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
AU730850B2 (en) 1997-10-28 2001-03-15 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
WO1999036099A1 (fr) 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Compositions a liberation controlee, leur procede de fabrication et leur utilisation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
BR9913887A (pt) 1998-09-18 2001-10-23 Basf Ag Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
JP3966693B2 (ja) 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
EP1598338B9 (en) * 2001-04-18 2009-11-18 Euro-Celtique S.A. 1-(4-piperidinyl)-1,3-dihydro-2h-indole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
CA2466915A1 (en) * 2002-01-28 2003-08-07 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
CN100402529C (zh) * 2002-09-09 2008-07-16 詹森药业有限公司 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
AU2004272077A1 (en) 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
EP1732928A2 (en) 2004-03-29 2006-12-20 Pfizer, Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
WO2006130416A2 (en) 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as orl-1 receptor modulators
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
TW201211028A (en) * 2010-08-10 2012-03-16 Dainippon Sumitomo Pharma Co Fused ring pyrrolidine derivatives
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014106238A1 (en) 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
CN108883103A (zh) * 2015-12-02 2018-11-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254895A1 (en) * 2000-01-20 2002-11-06 Eisai Co., Ltd. Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
EP1308439A1 (en) * 2000-08-10 2003-05-07 Welfide Corporation Proline derivatives and use thereof as drugs
WO2004056830A1 (en) * 2002-12-19 2004-07-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2008060621A2 (en) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
WO2011029915A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Ether derivatives of bicyclic heteroaryls
WO2011101409A1 (en) * 2010-02-19 2011-08-25 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EP2878601A1 (en) * 2012-07-27 2015-06-03 Riken Agent for treating or controlling recurrence of acute myelogenous leukemia
WO2014157687A1 (ja) * 2013-03-29 2014-10-02 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４－トリアジン－６－カルボキサミド誘導体
WO2014174021A1 (en) * 2013-04-24 2014-10-30 Janssen Pharmaceutica Nv 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors for the treatment of cancer
WO2014184069A1 (en) * 2013-05-14 2014-11-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
WO2015044269A1 (en) * 2013-09-26 2015-04-02 Janssen Pharmaceutica Nv NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
WO2016062789A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New thienopyrimidine derivatives as nik inhibitors
WO2016062791A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERRARI FEDERICA ET AL: "In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 793, 22 October 2016 (2016-10-22), pages 1 - 13, XP029830223, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2016.10.025 *
See also references of WO2017096323A1 *

Also Published As

Publication number Publication date
EP4455145A3 (en) 2025-03-12
AU2016365400B2 (en) 2022-04-07
JP7472175B2 (ja) 2024-04-22
EP4455145A2 (en) 2024-10-30
JP2018536716A (ja) 2018-12-13
AU2016365400C1 (en) 2022-11-10
JP2024083529A (ja) 2024-06-21
KR102781748B1 (ko) 2025-03-13
WO2017096323A1 (en) 2017-06-08
AU2022202862B2 (en) 2024-03-28
JP2022036285A (ja) 2022-03-04
AU2024204437A1 (en) 2024-07-18
IL259726A (en) 2018-07-31
CA3006966A1 (en) 2017-06-08
KR20240132125A (ko) 2024-09-02
JP7011596B2 (ja) 2022-02-10
AU2022202862A1 (en) 2022-05-19
JP2024003167A (ja) 2024-01-11
IL259726B (en) 2021-10-31
AU2016365400A1 (en) 2018-06-21
EP3383390A1 (en) 2018-10-10
CN108883103A (zh) 2018-11-23
KR20180094940A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
IL286923A (en) G protein-coupled receptor (gpcr) modulation by imipridones
DK3368060T3 (da) Glugacon-receptor-agonister
MA43382A (fr) Modulateurs des récepteurs des chimiokines
IL261461B (en) Methods of treating depression using orexin-2 receptor antagonists
IL259947B (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
AP2016009445A0 (en) Muscarinic receptor agonists
EP3295474A4 (en) LOAD CONTROL FOR HETEROEPITAXIA
IL250888A0 (en) Transmuted piperidine compounds
DK3189043T3 (da) Terapeutiske forbindelser som hæmmere af orexin-1-receptoren
DK3212637T3 (da) Dopamin-d3-receptorantagonistforbindelser
EP3464336A4 (en) LINKS
EP3368336A4 (en) VEHICLE HEAD
EP3096791C0 (en) IMMUNOMODULATING COMPOUNDS
EP3310352A4 (en) CRYSTALLINE COMPOUNDS
EP3405455A4 (en) 2-oxindole CONNECTIONS
DK3277690T3 (da) Spirocykliske forbindelser
DK3334721T3 (da) Cgrp-receptorantagonister
IL259726B (en) Nociceptin piperidinyl receptor compounds
MA49880A (fr) Composés anticancéreux
MA43791A (fr) Composés de carbapénème
FR3026427B1 (fr) Taquert coinceur pour echelle haubanable
EP3388149A4 (en) COLUMN STRUCTURE FOR BIOCHIP
EP3298005A4 (en) ANTI CANCER COMPOUNDS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/04 20060101AFI20190709BHEP

Ipc: A61K 31/44 20060101ALI20190709BHEP

Ipc: C07D 471/10 20060101ALI20190709BHEP

Ipc: C07D 405/14 20060101ALI20190709BHEP

Ipc: C07D 401/14 20060101ALI20190709BHEP

Ipc: A61P 29/00 20060101ALI20190709BHEP

Ipc: C07D 471/04 20060101ALI20190709BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20191023

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/14 20060101ALI20191017BHEP

Ipc: C07D 471/04 20060101ALI20191017BHEP

Ipc: C07D 471/10 20060101ALI20191017BHEP

Ipc: A61P 29/00 20060101ALI20191017BHEP

Ipc: A61K 31/44 20060101ALI20191017BHEP

Ipc: C07D 401/14 20060101ALI20191017BHEP

Ipc: C07D 401/04 20060101AFI20191017BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261973

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220510

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTRAEA THERAPEUTICS, LLC